Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 30455
Bifidobacterium lactis Fermented Milk Was Not Effective for Helicobacter pylori Eradication: A Prospective, Randomized, Double-Blind, Controlled Study

Authors: R. C. Barbuti, M. N. Oliveira, N. P. Perina, C. Haro, P. Bosch, C. S. Bogsan, J. N. Eisig, T. Navarro-Rodriguez


The management of Helicobacter pylori (H. pylori) eradication is still a matter of discussion, full effectiveness is rarely achieved, and it has many adverse effects. The use of probiotics may be associated with better eradication rates and possibly prevention of adverse events due to antibiotic therapy. The present clinical study was undertaken to evaluate the efficacy of a specially designed fermented milk product, containing Bifidobacterium lactis B420, on the eradication of H. pylori infection in a prospective, randomized, double-blind, controlled study in humans. Four test fermented milks (FM) were specially designed in which counts of viable cells in all products were 10^10 Log CFU. 100 mL-1 for Bifidobacterium lactis - Bifidobacterium species 420. 190 subjects infected with H. pylori, with previous diagnosis of functional dyspepsia according to Rome III criteria entered the study. Bifidobacterium lactis B420, administered twice a day for 90 days was not able to eradicate H. pylori in Brazilian patients with functional dyspepsia.

Keywords: Probiotics, Helicobacter pylori, antibacterial therapy, Bifidobacteria Fermented milk

Digital Object Identifier (DOI):

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1893


[1] J. Tack, N. J. Talley, “Functional dyspepsia – symptoms, definitions and validity of the Rome III criteria”, Nat Rev Gastroenterol Hepatol. vol. 10, pp. 134–41, 2013.
[2] S. L. Chen, “A review of drug therapy for functional dyspepsia”, J. of Dig. Diseases, vol. 14, pp. 623–625, 2013.
[3] J. C. Yang, C. W. Lu and C. J. Lin, “Treatment of Helicobacter pylori infection: Current status and future concepts”, World J Gastroenterol vol. 14, n. 20(18), pp. 5283-5293, May 2014.
[4] C. Porras, J. Nodora, R. Sexton, C. Ferreccio, S. Jimenez, R. L. Dominguez, P. Cook, G. Anderson, D. R. Morgan, L. H. Baker, E. R. Greenberg and R. Herrero, “Epidemiology of Helicobacter pylori infection in six Latin American countries” (SWOG Trial S0701). 2012.
[5] T. Navarro-Rodriguez, F. M. Silva, R. C. Barbuti, R. Mattar, J. P. Moraes-Filho, M. N. Oliveira, C. S. Bogsan, D. Chinzon and J. N. Eisig, “Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study”. BMC Gastroenterology, vol. 13, pp. 56, 2013.
[6] L. G. Coelho, I. Maguinilk, S. Zaterka, J. M. Parente, M. do Carmo Friche Passos and J. P. Moraes-Filho, “3rd Brazilian Consensus on Helicobacter pylori”, Arq Gastroenterol. p. 50, Apr 2013.
[7] G. Felga, F. M. Silva, R. C. Barbuti, T. Navarro-Rodriguez, S. Zaterka and J. N. Eisig, “Claritromycin-based triple therapy for Helicobacter pylori in peptic ulcer patients”, J Infect Dev Countries, vol. 24, n. 11, pp. 712-6, Nov 2010.
[8] A. Sachdeva, S. Rawat and J. Nagpal, “Efficacy of fermented milk and whey proteins in Helicobacter pylori eradication: A review”, World J Gastroenterol, vol. 21, n. 3, pp. 724-737, January 2014.
[9] J. M. B. Vitor and F. F. Vale, “Alternative therapies for Helicobacter pylori: probiotics and phytomedicine”, Fems Immunology and Medical Microbiology, vol. 63, pp. 153-164, 2011.
[10] D. Lesbros-Pantoflickova, I. Corthesy-Theulaz and A. L. Blum, “Helicobacter pylori and probiotics”, Journal of Nutrition vol. 137, pp. 812S-818S, 2007.
[11] S. Li, X. Huang, J. Z. Sui, S. Y. Chen, Y. T. Xie, Y. Deng, J. Wang, L. Xie, T. J. Li, Y. He, Q. L. Peng, X. Qin and Z. Y. Zeng, “Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children”, Eur J Pediatr. vol. 173, pp. 153–161, 2014.
[12] C. P. M. Felley, “Probiotics and Helicobacter pylori”, Best Pract Res Clin Gastroenterol. vol. 17, pp. 785-791, 2003.
[13] J. A. da Silva Medeiros, T. M. F. O. Goncalves, L. Boyanova, M. I. de Correia Pereira, J. N. da Silva Paiva de Carvalho, A. M. de Sousa Pereira and A. M. Silverio Cabrita, “Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone” European Journal of Clinical Microbiology & Infectious Diseases vol. 30, pp. 555-559, 2011.
[14] M. Gotteland, O. Brunser and S. Cruchet, “Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori”, Alimentary Pharmacology & Therapeutics vol. 23, pp. 1077- 1086, 2006.
[15] Y. J. Yang and B. S. Sheu, “Probiotics-Containing Yogurts Suppress Helicobacter pylori Load and Modify Immune Response and Intestinal Microbiota in the Helicobacter pylori-Infected Children” Helicobacter vol. 17, pp. 297-304, 2012.
[16] P. Michetti, “Lactobacilli for the management of Helicobacter pylori nutrition” The International Journal of Applied and Basic Nutritional Sciences vol. 17, pp. 268-269. 2001.
[17] C. Sunanliganon, D. Thong-Ngam, S. Tumwasorn and N. Klaikeaw, “Lactobacillus plantarum B7 inhibits Helicobacter pylori growth and attenuates gastric inflammation”, World Journal of Gastroenterology vol. 18, pp. 2472-2480, 2012.
[18] B. S. Sheu, J. J. Wu, C. Y. Lo, H. W. Wu, J. H. Chen, Y. S. Lin, and M. D. Lin, “Impact of supplement with Lactobacillus- and Bifidobacteriumcontaining yogurt on triple therapy for Helicobacter pylori eradication”, Alimentary Pharmacology & Therapeutics vol.16, pp. 1669-1675. 2002.
[19] Z. H. Wang, Q. Y. Gao and J. Y. Fang, “Meta-Analysis of the Efficacy and Safety of Lactobacillus-containing and Bifidobacterium-containing Probiotic Compound Preparation in Helicobacter pylori Eradication Therapy”, Journal of Clinical Gastroenterology vol. 47, pp. 25-32. 2013.
[20] M. Wang, S. Ahrnes, B. Jeppsson and G. Molin, “Comparison of bacterial diversity along the human intestinal tract by direct cloning and sequencing of 16S rRNA genes”, FEMS Microbiology Ecology vol. 54, pp. 219-231. 2005.
[21] J. Korzenik, C. Kitts, A. Pittler, A. Englebrektson, M. Sanders and T. Klaenhammer, “A randomized, double-blind, controlled trial of probiotics to minimize the disruption of gut flora as assessed by 16s RNA terminal restriction fragment length polymorphism and culture enumeration in healthy subjects undergoing antibiotic therapy”, Gastroenterology vol. 128, pp. A662-A662. 2005.
[22] B. Foligne, S. Nutten, C. Grangette, V. Dennin, D. Goudercourt, S. Poiret, J. Dewulf, D. Brassart, A. Mercenier and B. Pot, “Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria”, World Journal of Gastroenterology vol. 13, pp. 236-243. 2007.
[23] J. Tack and N. Talley, “Gastroduodenal disorders”, Am J Gastroenterol vol. 105, pp. 757-763. 2010.
[24] P. Malfertheiner, F. Megraud, C. A. O'Morain, J. Atherton, A. T. Axon, F. Bazzoli, G. F. Gensini, J. P. Gisbert, D. Y. Graham, T. Rokkas, E. M. El-Omar and E. J. Kuipers, “Management of Helicobacter pylori infection – the Maastrich IV/ Florence Consensus Report, European Helicobacter Study Group”. Gut, vol. 61, n. 5, pp. 646-64. May 2012.
[25] M. Aguilera, M. Cerdà-Cuéllar and V. Martínez, “Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice”, Gut Microbes. vol. 22, pp. 1-14. Dec 2014
[26] R. Zhu, K. Chen, Y. Y. Zheng, H.W. Zhang, J. S. Wang, Y. J. Xia, W. Q. Dai, F. Wang, M. Shen, P. Cheng, Y. Zhang, C. F. Wang, J. Yang, J. J. Li, J. Lu, Y. Q. Zhou and C. Y. Guo, “Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy”, World J Gastroenterol. vol.21, n. 20, pp. 18013-21, Dec 2014.